OyaGen Inc.-developing anti-HIV drug therapies using editing enzyme technology

OyaGen in the News


Publications from OyaGen
Miller JH, Presnyak V, Smith HC (2007) The dimerization domain of HIV-1 viral infectivity factor Vif is required to block APOBEC3G incorporation with virions. Retrovirology 2007, 4:81

News Features

UR to Receive Millions for Ongoing AIDS Research
Rochester, NY -  Rochester Business Journal, March 12, 2007

OyaGen blazing path toward anti-AIDS drug
Rochester, NY -  Democrat & Chronicle, September 1, 2005

Study Holds Promise For New Way To Fight HIV
University of Rochester Press Release - September 1, 2005

OyaGen Scientific Advisor Board Meeting - photo
New York, NY - April, 2005

Television interview with Dr. Smith         
Rochester, NY  - R News, Cable Channel 9, January, 2004
     Windows Media Player  -
     QuickTime Player  -

Television interview with Dr. Smith 
Rochester, NY  - WOKR13.TV - News Source 13, January, 2004
     Windows Media Player
     QuickTime

Rochester Start-Up Offers Groundbreaking Discovery in HIV Research
Company Press Release

UR Invests in Anti-HIV Startup
Rochester, NY -  Democrat & Chronicle, January 12, 2004

If you need to download a free QuickTime Player go to http://www.apple.com/quicktime/download/